Call to establish 'Centers of Excellence' for pituitary diseases

November 20, 2012

Philadelphia, Pa. (November 20, 2012) - The time has come to develop a pituitary "centers of excellence" (CoE) designation for hospitals with high-level surgical skills and other capabilities needed to provide state-of-the-art care for patients with pituitary tumors, according to an article in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Recent advances in surgical and medical management--along with the high prevalence and impact of pituitary tumors--warrant development of a voluntary system for designating pituitary centers of excellence, according to the special article by four leading U.S. neurosurgeons including Daniel Kelly and Nancy McLaughlin (John Wayne Cancer Institute & Saint John's Health Center, Santa Monica, CA), Edward Laws, (Brigham & Women's Hospital, Boston, MA) and Nelson Oyesiku (Emory University, Atlanta, GA), as well as a leading endocrinologist (Laurence Katznelson, Stanford University, Palo Alto, CA).

Designation Recognizes Surgical Skills and Coordinated Care for Pituitary Tumors

Tumors of the pituitary gland, located directly under the brain in the skull base, pose difficult challenges in both diagnosis and treatment. Known as the body's "master gland," the pituitary produces hormones that control a wide range of bodily functions. In recent years, studies have shown that pituitary adenomas and other related tumors are more common than previously thought--affecting perhaps 1 out of 1,000 people. These tumors can lead to conditions of hormonal excess such as acromegaly, Cushing's disease and prolactinoma, as well as hormonal loss, visual loss and headaches.

The idea of a CoE designation reflects specialized skills and expertise needed to provide top-level care for patients with particular types of problems. Perhaps the best-known example is the designation of level I to IV trauma centers, based on criteria such as the volume of severely injured patients treated, levels of specialist staffing, and the presence of educational and outreach programs.

The authors believe it's time for a similar approach to identifying hospitals and medical centers with the capacity to provide optimal clinical management for patients with pituitary tumors. Care is best provided in a "multidisciplinary collaborative environment," including neurosurgeons and endocrinologists with special experience in managing pituitary disorders. The treatment team should also include a wide range of other medical and surgical subspecialists who play important roles in managing these complex cases, such as neuro-ophthalmologists, radiation oncologists and otolaryngologists (ENT).

The call for a CoE designation reflects the rapid evolution of highly specialized surgical techniques for pituitary tumors, known as transsphenoidal surgery, increasingly performed with endoscopy, as well as new medical approaches to treating the hormonal abnormalities these tumors can produce. Advances in radiology and pathology have also raised the standard of skills needed for diagnosis and management.

As with other advanced surgical procedures, studies have shown that centers performing a larger volume of transsphenoidal surgeries achieve better outcomes with lower complication rates. Such high levels of volume and expertise are also essential for training the next generation of pituitary surgeons, who may not be getting the experience they need at some residency programs.

"[O]ptimal care for pituitary patients is best provided by experienced practitioners, working in a collaborative environment using state-of-the-art techniques and therapies," the authors write. They outline a "preliminary proposal" for a pituitary CoE designation, based on three key missions: The authors acknowledge that many questions remain to be answered, such as what organization would oversee the effort and how to ensure that expertise is adequately distributed across regions. As time goes on, it will be important to show that pituitary centers of excellence are truly effective in improving patient outcomes and reducing health care costs. They conclude, "Such an effort would enhance patient care, increase public awareness, promote training and expertise, and advance research in the management of pituitary tumors and related hormonal disorders."
-end-
About Neurosurgery

Neurosurgery, the Official Journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.

About Lippincott Williams & Wilkins

Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2011 annual revenues of €3.4 billion ($4.7 billion).

Wolters Kluwer Health

Related Tumors Articles from Brightsurf:

A viable vaccine for tough tumors
While immunotherapies work well for some cancers, others are immune-resistant and condemn patients to the severe side effects of long-term chemo treatment.

Women could conceive after ovarian tumors
Women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.

Attacking tumors from the inside
A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer (NSCLC), helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

Directing nanoparticles straight to tumors
Modern anticancer therapies aim to attack tumor cells while sparing healthy tissue.

A solid vaccine for liquid tumors
Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years.

Evolutionarily novel genes work in tumors
A team of scientists from Peter the Great St. Petersburg Polytechnic University studied the evolutionary ages of human genes and identified a new class of them expressed in tumors -- tumor specifically expressed, evolutionarily novel (TSEEN) genes.

Identification of all types of germ cells tumors
Germ cell tumors were considered very heterogeneous and diverse, until recently.

Laser light detects tumors
A team of researchers from Jena presents a groundbreaking new method for the rapid, gentle and reliable detection of tumors with laser light.

Better prognosticating for dogs with mammary tumors
For dogs with mammary tumors, deciding a course of treatment can depend on a variety of factors, some of which may seem to contradict one another.

The evolution of brain tumors
Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas.

Read More: Tumors News and Tumors Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.